



Erratum: Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Frontiers Production Office
production.office@frontiersin.org

Specialty section:

This article was submitted to
Vaccines and
Molecular Therapeutics,
a section of the journal
Frontiers in Immunology

Received: 06 August 2021

Accepted: 06 August 2021

Published: 20 August 2021

Citation:

Frontiers Production Office (2021)
Erratum: Administration of Multivalent
Influenza Virus Recombinant
Hemagglutinin Vaccine in
Combination-Adjuvant Elicits
Broad Reactivity Beyond the
Vaccine Components.
Front. Immunol. 12:754535.
doi: 10.3389/fimmu.2021.754535

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

Keywords: vaccine, influenza, adjuvant, CpG, MPLA, ADDAVAX®, hemagglutinin

An erratum on

Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components

By Hernandez-Davies JE, Felgner J, Strohmeier S, Pone EJ, Jain A, Jan S, Nakajima R, Jasinskas A, Strahsburger E, Krammer F, Felgner PL and Davies DH (2021). *Front. Immunol.* 12:692151. doi: 10.3389/fimmu.2021.692151

Due to a production error, there was a mistake in **Figure 6** as published. Part of the y axis title and scale in **Figure 6B** was obscured by a white area.

The corrected **Figure 6** appears below. The publisher apologizes for this mistake.

The original version of this article has been updated.

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 6 | Boosting is required to generate virus neutralization after receiving trivalent vaccine. **(A)** Means of signals at different time points for HA0 and HA1 variants of H1, H5 and H7 after administration of trivalent vaccine. **(B)** HI assay titers of individual sera used in panels **(A, B)** against PR8 reassortant influenza viruses expressing Cal09 H1, VN04 H5 and AH13 H7, respectively. Horizontal dotted line, 1/40 dilution cutoff (\log_2 of 40 = 5.32) **(C)** serial dilutions of plasma from a representative mouse to determine titers at different time points using microarrays; shown are means of H1, H5 and H7 variants after serial dilutions. All data are representative of two separate experiments. PB1, post first boost; PB2, post second boost; red arrows, boosts. **** $P < 0.0001$; *** $P \leq 0.001$; ** $P \leq 0.01$; * $P < 0.05$.